KOD vs. OCS, ZYME, NTLA, NUVB, AVBP, IMNM, PHAR, CMRX, CDMO, and GYRE
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Oculis (OCS), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Immunome (IMNM), Pharming Group (PHAR), Chimerix (CMRX), Avid Bioservices (CDMO), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Kodiak Sciences vs. Its Competitors
Oculis (NASDAQ:OCS) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
In the previous week, Kodiak Sciences had 1 more articles in the media than Oculis. MarketBeat recorded 8 mentions for Kodiak Sciences and 7 mentions for Oculis. Kodiak Sciences' average media sentiment score of 0.11 beat Oculis' score of -0.09 indicating that Kodiak Sciences is being referred to more favorably in the news media.
Oculis received 15 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 91.89% of users gave Oculis an outperform vote while only 26.76% of users gave Kodiak Sciences an outperform vote.
Oculis has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.
Oculis has higher revenue and earnings than Kodiak Sciences. Oculis is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences has a net margin of 0.00% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat Kodiak Sciences' return on equity.
Oculis currently has a consensus price target of $35.33, indicating a potential upside of 80.00%. Kodiak Sciences has a consensus price target of $9.00, indicating a potential upside of 123.33%. Given Kodiak Sciences' higher probable upside, analysts clearly believe Kodiak Sciences is more favorable than Oculis.
22.3% of Oculis shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Kodiak Sciences beats Oculis on 9 of the 17 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KOD) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy KOD Stock Free KOD Stock Alerts